Updated October 12, 2020
- FDA has only approved two biosimilars in 2020.
- No biosimilars have launched in the U.S. since April 2020.
- EMA approves first Novolog® (insulin aspartate), third and fourth Avastin® (bevacizumab), and sixth Herceptin® (trastuzumab) biosimilars.
As pharmaceutical drug costs attract increasing media attention and political scrutiny, a growing number of biosimilar drugs